Tilray® Exports 2:100 CBD Oil to the United Kingdom
Sep. 11, 2018
NANAIMO, British Columbia--(BUSINESS WIRE)--Sep 11, 2018--Tilray Inc. (NASDAQ:TLRY), a global leader in cannabis research, production and distribution, announced today that Tilray 2:100, a product produced at Tilray’s federally licensed, Good Manufacturing Practice (GMP)-certified facility in Canada, was successfully imported into the United Kingdom, to supply a pediatric patient in need.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180911005234/en/
Tilray 2:100 (Photo: Business Wire)
The changing regulatory measures in the United Kingdom (UK) previously prohibited the use of medical cannabis. However, in July 2018, Home Secretary Sajid Javid announced that clinicians will now legally be able to prescribe cannabis-derived medicines to patients with an exceptional clinical need noting “recent cases involving sick children made it clear to me that our position on cannabis-related medicinal products was not satisfactory.”
With government-approved compassionate access, the UK-based patient suffering from a rare form of epilepsy, now has reliable access to Tilray 2:100, the product used as the primary medicine in a clinical trial testing the efficacy and tolerability of cannabis-derived medicine as treatment for pediatric epilepsy. The trial was conducted in partnership with The Hospital For Sick Children (SickKids) in Toronto, Canada and published promising results in August.
In a press release issued by SickKids, Dr. Blathnaid McCoy, Staff Neurologist at SickKids who conducted the clinical trial and authored the research, said “In the participants who reached the target treatment dose we saw a statistically significant reduction in motor seizures, and an increase in seizure-free days compared to those who did not reach the target dose. We observed promising clinically beneficial effects including a reduction in seizure frequency and improvements in certain aspects of adaptive functioning and quality of life measures.”
The Tilray oral solution imported to the United Kingdom contains 100 mg/ml cannabidiol (CBD) and 2mg/ml tetrahydrocannabinol (THC), the same ratio of active cannabinoids Tilray used in the recent clinical trial led by SickKids. This ratio of the active cannabinoids was selected after Tilray conducted extensive research on published data of cannabinoids to treat seizures. Tilray 2:100 was deemed safe and well tolerated in pediatric patients by the researchers.
About Tilray® Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients in eleven countries spanning five continents.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005234/en/
CONTACT: For Tilray
US & Canada
Chrissy Roebuck, +1-416-560-5712
Justin Doherty, +44 (0)7768-330223
Katie Turner, +1-646-277-1228
KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA CANADA IRELAND
INDUSTRY KEYWORD: TRANSPORT HEALTH ALTERNATIVE MEDICINE OTHER TRANSPORT PHARMACEUTICAL BABY/MATERNITY CHILDREN PARENTING RESEARCH CONSUMER SCIENCE MANAGED CARE
SOURCE: Tilray Inc.
Copyright Business Wire 2018.
PUB: 09/11/2018 08:00 AM/DISC: 09/11/2018 08:01 AM